Companies: 10,795·Total market cap: $144.5T
Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLANASDAQHealthcare● Active
$105.25
$-3.42(-3.15%)
Market Cap$1.2B
P/E Ratio
52W High$151.18
52W Low$20.2
Overview

Palvella Therapeutics, Inc. (PVLA) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · PVLA · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-4.17pvla eps ttm · pvla earnings per shareEarnings history
PE Ratio (TTM)pvla pe ratio ttm · pvla price to earningsPE Ratio deep dive
Revenue (TTM)0.00pvla revenue ttm · pvla annual revenueFull revenue history
Dividend YieldNo Dividenddoes pvla pay dividends · pvla dividend yieldDividend history
Shares Outstanding11.3Mpvla shares outstanding · pvla floatShares outstanding history
Next EarningsAug 13, 2026Est.pvla earnings date · pvla next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
palvella therapeutics, inc. revenue · pvla revenue 2025
FY 2025Net Income-$41.7M▼ 139.27% YoY
202320242025
palvella therapeutics, inc. net income · pvla profit 2025
FY 2025EPS$-3.71▲ +52.62% YoY
202320242025
pvla eps · palvella therapeutics, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$49.3MEPS: $-4.17View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy11 analystsis pvla a buy · pvla analyst rating
Strong Buy
1
Buy
10
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$143.00Low
$105.25Current
$207.67Avg Target97.31% upside
$255.00High
pvla price target · pvla 12 month forecast

Total: 11 · Buy rate: 100.0%

The PVLA analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $207.67, representing +97.31% upside from the current price of $105.25.

Stock Performance

Full History
1D-3.15%
1W-2.31%
1M-13.22%
3M-21.68%
YTD+0.55%
1Y+295.23%
5Y+519.12%

About Palvella Therapeutics, Inc.

CEOWesley H. Kaupinen
IPO DateJan 2, 2015
Employees14
CountryUS

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and…

what is palvella therapeutics, inc. · pvla stock overview · palvella therapeutics, inc. company profile · who is palvella therapeutics, inc. ceo · pvla NASDAQ · palvella therapeutics, inc. headquarters · palvella therapeutics, inc. business segments

About Stock Overview & Key Data

Palvella Therapeutics, Inc. (PVLA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 2, 2015. As of the latest trading session, PVLA stock price is $105.25, with a market capitalization of $1.2B. The stock has returned +295.23% over the past 12 months and +0.55% year-to-date.

According to 11 Wall Street analysts, the consensus rating for Palvella Therapeutics, Inc. stock is Buy, with an average 12-month price target of $207.67. In fiscal year 2025, Palvella Therapeutics, Inc. reported revenue of — and net income of -$41.7M. For detailed data — including Palvella Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Palvella Therapeutics, Inc. (PVLA) stock price is $105.25. The stock is traded on NASDAQ under the ticker symbol PVLA. The 52-week range is $20.20 – $151.18.

PVLA stock pricePVLA quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice